Navigation Links
Dey, L.P. Settles State of Alabama Pricing Litigation
Date:1/9/2008

NAPA, Calif., Jan. 9 /PRNewswire/ -- Dey, L.P. today announced that it has settled a lawsuit brought against it and other companies by the State of Alabama in January 2005 pertaining to Medicaid reimbursements paid by the state to pharmacists and other healthcare providers. In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, $750,000 of which accounts for outside legal fees and expenses.

As part of the acquisition agreement between Mylan Inc. (Dey's parent company) and Merck KGaA (Dey's former parent company), Merck has agreed to indemnify Mylan in connection with this settlement and for all liability for all pending and future related Medicaid reimbursement lawsuits involving Dey.

As part of the settlement, the state acknowledges that the settlement does not constitute admission or evidence of fault, liability or unlawful conduct by Dey.

About Dey, L.P.

Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey, L.P. include http://www.dey.com, http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.du
'/>"/>

SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Park Dental Doctor Group Settles Litigation With Service Provider
2. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
3. Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter
4. Sunrise Settles Litigation Regarding Its 2007 Annual Meeting
5. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
6. Global Med Technologies(R) Adds Eighth SafeTrace Tx(R) Client in New York State
7. Fatherhood Tied to Higher Prostate Cancer Risk
8. Fatherhood linked to prostate cancer risk
9. Michigan Quality Council (MQC) Names Oakwood Healthcare Inc. 2007 State Quality Award Recipient
10. RxElite Registration Statement Suspended
11. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Approved lymphoma drug shows promise in early tests against bone cancer 60780 1Approved lymphoma drug shows promise in early tests against bone cancer 60780 2School Violence Drops With Federal Program 60777 1School Violence Drops With Federal Program 60777 2DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products Therapeutic Biologics and Vaccines 60773 1DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products Therapeutic Biologics and Vaccines 60773 2DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products Therapeutic Biologics and Vaccines 60773 3